Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study

Autor:	Richard N. Fedorak, M. S. Linton, Karen I. Kroeker, Darryl K. Fedorak, Levinus A. Dieleman
Rok vydání:	2013
Předmět:	Adult Male Epstein-Barr Virus Infections Herpesvirus 4 Human medicine.medical_specialty Adolescent Population Inflammatory bowel disease Serology Cohort Studies Young Adult Age Distribution Crohn Disease Internal medicine Azathioprine Prevalence medicine Humans Seroprevalence Pharmacology (medical) Prospective Studies Young adult education Prospective cohort study Antigens Viral Aged education.field_of_study Hepatology business.industry Gastroenterology Middle Aged medicine.disease Ulcerative colitis Immunoglobulin M Immunoglobulin G Immunology Colitis Ulcerative Female business Immunosuppressive Agents Cohort study
Zdroj:	Alimentary Pharmacology & Therapeutics. 38:1248-1254
ISSN:	0269-2813
Popis:	Summary Background The Epstein–Barr Virus (EBV) is truly prolific, with a prevalence of more than 90% in the adult human population. There are, however, little data available on the prevalence of EBV among patients with Inflammatory Bowel Disease (IBD), a population that is frequently immunosuppressed and thus at risk for severe, often fatal, primary infection. Aim To identify the prevalence of EBV in a population of patients with IBD and to compare it with that of the general population. Methods A database of 2500 IBD patients previously followed at the University of Alberta IBD Centre was queried; 60 of these patients were randomly chosen to participate. A total of 220 patients attending the IBD Centre for clinical appointment were also prospectively asked to participate. Participants completed serological testing for VCA-IgM, VCA-IgG and EBNA-IgG, to determine prior EBV exposure. Results A total of 263 patients underwent testing. Results for EBV seroprevalence of specific age groups were as follows: 18–20 years (n = 17), 29% seronegative; 21–25 years (n = 31), 29% seronegative; 26–30 years (n = 35), 31–35 years (n = 18) and 36–40 years (n = 25), 100% seropositive. Finally, 3% of those older than 40 (n = 117) were seronegative. EBV seroprevalence was similar for Crohn's disease and ulcerative colitis. Azathioprine was associated with seropositivity (P = 0.048). Conclusion The prevalence of EBV seronegativity in the IBD population aged 18–25 years was similar to that described in the general population, and above age 25 years, seropositivity approached 100%.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614f185bbc6e290b290b16d57db101a4 https://doi.org/10.1111/apt.12503 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.